- Report
- October 2025
Global
From €4352EUR$4,900USD£3,802GBP
- Report
- June 2025
- 100 Pages
Global
From €4352EUR$4,900USD£3,802GBP
- Report
- April 2025
Global
From €4352EUR$4,900USD£3,802GBP
- Report
- February 2025
- 209 Pages
Global
From €2176EUR$2,450USD£1,901GBP
- Report
- October 2025
Global
From €4352EUR$4,900USD£3,802GBP
- Report
- February 2025
- 120 Pages
Global
From €5284EUR$5,950USD£4,616GBP
- Report
- November 2025
- 193 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 182 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 199 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 184 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 180 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 196 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 190 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 187 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 188 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 184 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 189 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 197 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 194 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP
- Report
- November 2025
- 184 Pages
Global
From €3148EUR$3,545USD£2,750GBP
€3498EUR$3,939USD£3,056GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more